The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

Early‐phase clinical trials using oral inhibitors of MEK, the mitogen‐activated protein kinase kinase, have demonstrated benefit for patients with neurofibromatosis type 1 (NF1)‐associated tumors, particularly progressive low‐grade gliomas and plexiform neurofibromas. Given this potential of MEK inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Klesse, Laura J., Jordan, Justin T., Radtke, Heather B., Rosser, Tena, Schorry, Elizabeth, Ullrich, Nicole, Viskochil, David, Knight, Pamela, Plotkin, Scott R., Yohay, Kaleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Symptom Management and Supportive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356675/
https://www.ncbi.nlm.nih.gov/pubmed/32272491
http://dx.doi.org/10.1634/theoncologist.2020-0069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356675/
https://www.ncbi.nlm.nih.gov/pubmed/32272491
http://dx.doi.org/10.1634/theoncologist.2020-0069

Ejemplares similares